Clinical and biomarker results from a phase II trial of combined cabozantinib and durvalumab in patients with chemotherapy-refractory colorectal cancer (CRC): CAMILLA CRC cohort
Article in Nature Communications (February 2024)
The most recent citing publications are shown below. View all 7 publications that cite this research output on Dimensions.
Article in Nature Communications (February 2024)
Article in Frontiers in Pharmacology (January 2024)
Article in Biotechnology and Bioengineering (December 2023)